Biotech Daily

Daily news on ASX-listed biotechnology companies

Back copies

This is the new library page. For articles prior to April 1, 2022. Go to the Archive (link above).

Dr Boreham’s Crucible: Micro-X; Ausbiotech Releases 10-Year Industry Strategy; Doherty Starts Sars-Cov-2 Vaccines Dosing; Amplia: Victoria Okays AMP945 Pancreatic Cancer Trial; EBR 15% Oppose Placement Facility; Genetic Signatures Appoints Caroline Waldron Director; Zelira Loses Former Chair Harry Karelis

CSL Vifor Acquisition Delayed; MTP Connect $894k For Atmo, Cortical Dynamics, Proteomics; MTP Connect Redi Fellowships; Race: Calvary Mater Approves Zantrene AML, MDS Trial; Ena In J&J-Barda ‘Blue Knight’ Initiative; Burnet, Orbis Work On Remote, Rural Diagnostics; Rhythm Final TGA Colostat Filing; Neurotech Scraps Washout For NTI164 Autism Trial; Incannex Completes Apirx Deal; Incannex Apirx Shares, Directors Stock EGM; JM Financial Takes 15.4% Of Mach7; Resmed Loses Sleep Head Jim Hollingshead

CSL Wins Right To Challenge US ‘Mexican Plasma Ban’; Next Science: ‘Xperience Kills Free-Floating, Biofilm Bacteria’; Immuron: US Navy Files IND For 2 Travelan Trials; Neuroscientific Applies For Emtinb Clinical Trial; Pharmaust Takes Dog Lymphoma Trial To The US; Monash’s Prof Jamie Rossjohn Elected To The Royal Society

Redhill To Raise $21.5m, Warrants; Pacific Edge Cxbladder Monitor Validation Study; Imugene Australian HER-Vaxx Gastric Cancer Trial Approved; Clinuvel Ready For Phase II Scenesse Vitiligo Trial; Total Brain: AARP $3.8m Brain Health Extension; Medical Developments: Endo Canada Penthrox Distributor; Osteopore, Maxoniq To Sell Osteomesh Products; Clarity ‘Unaffected By Novartis Drug, Trial Halt’; PYC VP-001 PK Results Support Human Trial; Bod Starts Marijuana Trial For Insomnia; Incannex IHL-216A ‘Restores Memory’ In Concussed Rats; Emyria Expands MDMA Analogues; Creso: Health Canada Approves Psilocybin Import; Bio-Melbourne Connecting Women Lunch ‘Sold-Out’; Artrya Appoints Dr Jack Lewin Adviser; Osprey Extends Voluntary Suspension; Perennial Reduces To 14% Of Microba

Dimerix: US FDA Approves Phase III DMX-200 FSGS Trial; Amplia: FDA Wants More AMP945 Data For Cancer Trial; Artrya, Huntsville Heart Centre For US Salix Study; Prescient PTX-200 AML Remission Expands Cohort; Mayne Receives Up To $4.8m Federal Manufacturing Grant; Imugene Tells ASX Query: ‘Not Aware Until May 2’; Immuron: Travelan For US Study Manufactured; Zelira Launches Itura Marijuana Cream In The Us; Nuheara Appoints John Luna US CEO; Roth Capital Adviser; Microba Appoints Patrick Moelk For North America Sales

Dr Boreham’s Crucible: Pro Medicus; Rhinomed Places $455k Shortfall; Total $4.9m; Opthea: ‘OPT-302, Lucentis Improves PCV’; Bio-Melbourne Women In Leadership Awards; Osprey To Cut Staff; Incannex Requests ‘Pre-Clinical Study Results’ Trading Halt; Immuron Appoints Anatara’s Steven Lydeamore CEO

Immutep: ‘IMP321 Enhances Immune Response’; Argenica Completes Toxicology Studies; Microba Identifies 3 Drug Candidates Ahead Of Schedule; BTC: Federal Reimbursement ‘Unchanged’; Analytica Receives $269k Federal R&D Tax Incentive; Audeara Partners With Healthia, Nextsense; Universal Biosensors: Viburnum Funds Options EGM; Richmond Hill Takes 5% Of Universal Biosensors; Anatara To Lose CEO Steven Lydeamore; Polynovo CEO Search Continues; Anita James Replaces Medical Developments CFO, Co Sec Mark Edwards

Ankere: Brandon, IP Group $10m For Inflammation; Alcidion $23m, 6-Year Defence Force Contract; Rhinomed Raises $1.1m; Total $4.5m; $532k Shortfall; Actinogen Xanamia Trial Takes Focus Back To Cognition; Emvision: Keysight ‘Fast Sweep VNAS’ For Brain Scanner; Botanix To Pay Brickell $24m For Sofpironium Bromide; Clinuvel: Final Data Backs 16mg Afamelanotide For Stroke; Rhythm Closes Final Trial Sites; Imricor 36% AGM Opposition To Directors’ Shares

Nova Eye: FDA Paves Way For Pivotal 2rt AMD Trial; Albany Medical Center Buys LNT Apas Independence; Firebrick Starts 2nd Nasodine For Common Cold Trial; Australian Patent For Inoviq Sub-B2m Protein; Avecho Receives $1m Federal R&D Tax Incentive; Osprey Takes ‘Funding Options’ Halt To Suspension; Botanix Requests ‘Dermatology Asset Acquisition’ Halt

All April Indices Down: BDI-40 6%, ASX200 1%, Big Caps 2%, NBI 10%; Imugene Loses Merck Keytruda Supply; Trial Unaffected; Biotron: ‘BIT225 Kills Established Sars-Cov-2, In Mice’; Epsilon $2.1m Placement Facility For Southport Operations; Respiri Raises $1.6m For US Commercialization; Inoviq Hires MP Biomedicals For Sub-B2m Protein; Emvision Requests ‘Strategic Agreement’ Trading Halt; Credit Suisse Below 5% In Mesoblast; Heramed ‘Outstanding Results’ For Herabeat Monitor Trial; Servatus Appoints Dr Uwe Buecheler Director; Resonance Appoints Liesl Ellies Co-Co Sec

Dr Boreham’s Crucible: Haemokinesis; MTP Connect: Biotech A ‘Powerhouse Of Job Creation’; Oncosil Places $4m, Rights Offer For $6m More; Oncosil: Madrid Hospital $550k For Pancreatic Cancer; Auscann Lends Eurocann $5m, Partner For ‘Mutual Interests’; Respiri Takes ‘Capital Raising’ Trading Halt To Suspension; Osprey Requests ‘Funding Options’ Trading Halt; Allan Gray Takes 12.3% Of Starpharma

Cochlear To Buy Denmark’s Oticon For $170m; Incannex Free ‘Loyalty’ Options Raise $23.6m; Adherium Improves Hailie Monitor Connectivity; FDA Grants Botanix BTX1801 QIDP For Golden Staph; Anteris, Yale Study Haemodynamic Function; Uscom Files Spirosonic Air FDA 510(K) Application; Paradigm Doses 1st US Patients In PPS Knee Pain Trial; Exopharm Pleads Schultz To ASX 26% Fall Query; Jason Carroll Takes 12.2% Of Island; Osteopore Appoints CTO Dr Jing Lim Coo

Protagonist Falls 50% On PN-943 Ulcerative Colitis Miss; Actinogen Xanamia Phase Ib Part A Trial Meets Endpoints; Alterity: UK MHRA Okays ATH434 MSA Trial; Woke, Macquarie Uni Trial Psilocybin For Depression; LBT: 5 Apas Independence Studies At Lisbon Conference; Nuheara 16% Oppose EGM Consolidation; Anteris 460k Directors’ Options AGM; Oncosil Requests ‘Capital Raising’ Trading Halt; Respiri Requests ‘Capital Raising’ Trading Halt; Cardiex Appoints Lesa Musatto US Director

Aroa Revenue Up 78% To $36.5m; Firebrick Starts Nasodine Sars-Cov-2 Trial; Bod Starts UK Marijuana ‘Long Covid-19’ Trial; Argenica: ARG-007 Maximum Tolerated Dose Established; Nuheara Licences Hewlett Packard ‘HP’ Trademark; MTP Connect Appoints Stuart Dignam CEO; Memphasys: Robert Cooke, Alison Coutts, Shane Hartwig; Audeara: Jesse Crooks, Istvan Nagy For Us, Euro Sales; Patrys: Rebecca Tunstall Corporate Development Head; Atomo Appoints Chandra Sukumar, Jim McMenamy, Anna Tucker; Optiscan Appoints Andrew Barker, Steven Smart, Daisy Liu

Dr Boreham’s Crucible: Resapp Health; Cann Group $15m NAB Loan; Renegotiates $50m Loan; Actinogen Requests ‘Trial Results’ Trading Halt; Tissue Repair To Release 3.8m Escrow Shares; State Street Below 5% In Polynovo; W Whitney George Takes 40.4% Of Rhinomed; Director Paul Lewis, Invia Take 5% Of Hydrix; Avita Loses Director Louis Drapeau; Adherium Appoints Francis White Business Development Head

CSL $5.4b Notes For Vifor Acquisition; Universal Biosensors Placement Raises $6m; $20m Rights To Go; Clarity Treats 1st Prostate Cancer Patient; Kazia 60mg Paxalisib ‘Safe’ For Glioblastoma; Triaxial Note; Cynata Enrols 1st CYP-006TK Diabetic Foot Ulcer Patients; Opthea EGM: 25% Oppose 2m Directors Options; Imex: 174k Free Directors’ Options AGM; Palla Loses Directors Sue MacLeman, Iain Ross, Stuart Black; Teri Thomas To Replace Volpara CEO Dr Ralph Highnam; Anteo Appoints Ewen Crouch Chair

Universal Biosensors To Raise $25m; Arovella: QIMR To Manufacture ALA-101; Medlab, Cultech NRGbiotic Distribution Deal; Australian Super Takes 5% Of Nanosonics, Again; Respiri Loses Director Dr Thomas Duthy

Protagonist: FDA To Rescind Rusfertide Breakthrough Status; Volpara Receipts Up 45% To $26m; Alcidion: NT Health $5m For Miya Precision Upgrade; Universal Biosensors Tn Antigen Cancer Test; Funding Halt; BTC: Federal Methodology ‘Potentially Inconsistent’; Pharmaust Receives $708k Federal R&D Tax Incentive; Immuron ‘Eligible’ For $5.4m US Travelan Funding; Heramed, Pediatrix Virtual Obstetrics Program ‘Promising’; State Street Takes 5% Of Polynovo

Dr Boreham’s Crucible: Volpara Health Technologies; Osteopore: 1st Cranial Implants Sales In Spain; Cardiex Files FDA 510(K) For Conneqt Companion Software; Emyria Completes EMD-RX5 Phase I Dosing; Cann Group Mildura Marijuana Plant Operational; Telix 192k Director Share Rights AGM; Antisense Receives $571k Federal R&D Tax Incentive; Peters Takes 14% Of Optiscan; Vaxxas Appoints Dan Devine CBO, General Counsel.

Oncosil: 1st Euro Pancreatic Cancer Commercial Device; Imugene Doses 2nd Checkvacc Breast Cancer Cohort; Ellume To ‘Vigorously Defend’ US Sars-Cov-2 Test Action; Neuroscientific: Emtinb Tox Studies Prepare For Human Trials; Emyria Hires Clinitrials For Phase III Marijuana Distress Trial; Australian Super Below 5% In Nanosonics

Telix TLX591 For Prostate Cancer Trial Approved; Chimeric: Wuxi Atu To Manufacture Car-T-Cell; Antisense 1-For-20 Bonus Options To Raise $36m For DMD Trial; FDA Fast Tracks Paradigm Zilosul For Osteoarthritis; Nuheara Files US FDA 510k For ‘Self-Fitting Hearing Aid’; Recce: Safe 1,000mg R327 Takes Trial To 2,000mg; Medlab Marijuana Nanocbd Awaits Final UK Import Okay; Zelira 99.4% Pass 175-To-1 Consolidation; Imugene To Release 28.3m Voluntary Escrow Shares; Proteomics Appoints Promarkerd Launch Advisory Board; Race CEO Mr Lynch, CSO Dr Tillett 50% Pro Rata Pay Rise

Pfizer To Pay $100m For Resapp Health; Victoria $60m For $206m Aikenhead Bio-Medical Centre; Telix: $6.7m For Eli Lilly Olaratumab Licence; Control Bionics, Double R&D Launch Neuronode In Japan; Recce: Hong Kong Patent For R327, R529; Chair Dr John Cullity Takes 5.6% Of Race; Atomo To Release 160m ASX Escrow Shares; Lumos Chair Sam Lanyon Interim CEO, CEO Rob Sambursky CMO; Cronos Loses Inaugural Chair Shane Tanner

Dr Boreham’s Crucible: Microba Life Sciences; Pro Medicus: $32m Visage 7 Deal With Inova Health; Rhinomed Insto Rights Raise $3.37m; Retail For $1.63m More; Pharmaust: $202k Fight-MND Grant; Alithia Trial Manager; Kazia: Paxalisib Potential For Child Brain Cancers; Imricor: $535k CEO Options, Directors’ Restricted Stock AGM; Correction: Emyria; Artrya To Release 5.8m ASX Escrow Shares; State Street Reduces To 5.9% Of Nanosonics

Victoria: QS Ranks Monash ‘Top Pharmacy, Pharmacology Uni’; Rhinomed $22m Canada Supply Deal; $5m Rights Offer; Monash Uni’s Dr Xiaodong Liu Wins $20k Victoria Premier’s Award; MTP Connect, Pathology Technology Diagnostics Plan; MTP Connect, Defence Bio-Security Database; Osteopore Ships 1st Cranial Implant To Colombia; Emyria Starts Phase I EMD-RX5 Trial; Alterity: MRI Shows Iron, Atrophy Correlation; Adalta: India Patent For AD-214; Cann Group Wins Mildura Marijuana Manufacture Permit; State Street Takes 6.1% Of Cochlear; Mesoblast Appoints Paul Hughes Co-Co Sec

Polynovo: Record $12m Q3 Revenue; Alcidion: $1.4m, 5-Year Deal With East Lancashire NHS; Zelira: DRCN Fails To Pay $990k Marijuana Licence Fee; 4D Starts XV Lung Scans At Providence St Joseph Hospital; Amplia Ready For Phase II AMP945 Pancreatic Cancer Trial; Race Ready For Phase I Zantrene AML, MDS Trial; Cann Group: GSK $170k To Evaluate Marijuana Satipharm; Correction: Arovella; Australian Super Takes 5% Of Nanosonics; Perennial Takes 15% Of Microba; Microba Appoints Prof Trent Munro Head Of Therapeutics; Medadvisor M-D Robert Read Drops CEO Role; US CEO Wanted

Microba Falls 28% On IPO For Gut Tests, Therapies; Resonance: Carpl To Validate Ferrismart, Hepafat-AI; Truscreen ‘Superior For Cervical Cancer Screening’; Prescient Opens PTX-100 T-Cell Lymphoma Expansion Cohort; Avita: ‘15 Recell Presentations For Burns Treatment’; Neurotech: Marijuana NTI164 ‘Safe, Tolerable’; Adalta Inhaled AD-214 Pre-Clinical Work ‘On-Track’; Inoviq Hires Researchdx To Develop Sub-B2M Cancer Test; Total Brain To Issue $1.3m Convertible Notes To Zoltan Varga; Biotron Receives $1.6m Federal R&D Tax Incentive; Arovella: Anagrelide For Cancer US Patent; VGI: US Patent For Tocotrienol Delivery; Clarity: Green CFO, Vickery Co Sec, Dr Iagaru Adviser

Telix: Illucix Prostate Cancer Imaging US Commercial Launch; Telix: Federal $23m For Collaborative Manufacturing; Biotech Daily Website Upgrade; Alcidion $2.8m Silverlink UK Hospital Renewals; Medadvisor Final Syneos Payment For Adheris; Total $46m; Micro-X, DMS To Include Rover Components; Rhythm Colostat Trial ‘Meets Endpoints’; Uscom, Foxconn China Manufacturing Agreement; Radiopharm: UCLA DUNP19 For Cancer Licence; IQ3 Administrators Seek Extension Due To ‘Complexities’; Argenica: Dr Liz Dallimore M-D; Dr Meghan Thomas Appointed; Clinuvel Appoints Prof Andrew Likierman Director; Invex Renews Dr Tom Duthy On $180k

March BDI-40 Up 1.2%, ASX200 Up 6.4%, Big Caps Up 1.4%, NBI Up 4.25%; Federal $20m For Pancreatic Cancer Research; Alcidion: $3m Miya Deal With Dartford & Gravesham NHS; Starpharma Viraleze UK Relaunch, Resolves MHRA Queries; Inoviq Expands UQ Exosome Ovarian Cancer Test Research; Resapp: Dartford & Gravesham NHS To Trial Resappdx; Creso, Brower, Medara Latin America Marijuana Deal; Cann Group: UK Approves Satipharm Marijuana Capsule; Imricor Adds Italy For ICMR Cardiac Ablation; Australian Ethical Takes 6.9% Of Impedimed; Starpharma Appoints Dr Jeff Davies Director; Neuroscientific Appoints Simon Scott, Dougal Thring; Botanix: Dr Patricia Walker CMO, Dr Howie McKibbon CCO; Clinuvel Extends CEO Dr Philippe Wolgen Contract 3 Years

February BDI-40 Down 12%, ASX200 Up 1%, Big Caps Up 3%, NBI Down 4%; Firebrick To Appeal TGA Nasodine Knock-Back; Avita H2 Revenue Up 37% To $19m, Loss Down 9% To $20m; Imex Revenue Up 22.5% To $13.3m, Loss Up 30% $4.7m; Hydrix H1 Revenue Up 1.5% To $5.2m, Loss Down 50.1% $2.4m; Creso Revenue Up 154% To $6.2m, Loss Down 6.3% To $30m; Epsilon Revenue Down 21% To $5.5m, Loss Down 15.4% To $9m; Cardiex H1 Revenue Down 12.6% To $2.3m, Loss Up 147% To $5.1m; Osteopore Revenue Down 26% To $1.1m, Loss Up 86% To $3.6m; Avecho Begins TPM-CBD Osteoarthritis Trial; Starpharma: ‘SPL7013 Reduces Omicron 95% In 1min, In-Vitro’; Cardiex Completes 10-For-1 Consolidation; ASX Suspends IQ3 On Accounts; Medical Developments Requests ‘FDA Hold Feedback’ Halt; Anteris Requests Capital Raising Trading Halt; Epsilon Requests ‘Valens Partnership’ Trading Halt; Alterity Below Nasdaq $US1 Bid Rule, Again; First Sentier Takes 6.7% Of Nanosonics; Cryosite Director Andrew Kroger Takes 43%

Clarity: China Grand Option, $1.75 Options Lapse; Hydrix Placement Raises $2.8m; Kazia: Paxalisib, Metformin, Ketogenic Diet Glioblastoma Trial; Patrys PAT-DX3 Stable Production Cell Line; Lumos H1 Revenue Down 38% To $7m, Loss Up 234% To $15m, Febridx; Total Brain H1 Revenue Up 171% To $5.4m, Loss Down 36% To $2.6m; Anteris Revenue Up 10% To $8m, Loss Up 50% To $23m; Nuheara H1 Revenue Down 57% To $3m, Loss Up 614% To $6m; Resonance H1 Revenue Down 8% To $1.9m, Profit To $225k Loss; Osprey Revenue Up 17% To $2.7m, Loss Down 25% To $14m; Universal Biosensors: Xprecia Prime Coagulation Test CE Mark; Dimerix: Remap-Cap Trial Pause; No DMX-200 Implication; Noxopharm Starts Veyonda Combo Sarcoma Trial; Creso: Canada Approves Psilocybin For PTSD Trial; Orthocell Plans 100k PA Striate Dental Membrane Units; China Patent For Cynata Cymerus Stem Cells; Incannex Lists ADRs On Nasdaq; Probiotec CEO Wesley Stinger Sells 1m Shares, Holds 6.4%; Nanomab Takes 10.7% In Radiopharm; Jason Peterson Below 5% In Zelira; Mesoblast Loses 18-Year Director Donal O’Dwyer; Linda Jenkinson Replaces Medadvisor Director, Chair Chris Ridd

Dr Boreham’s Crucible: Firebrick Pharma; Victoria $470k For Avipep Lymphoma Treatment; Neuren: FDA Approves Angelman Syndrome Trial; Creso Raises $5m; Mayne H1 Revenue Down 6% To $196m; Loss Down 72.2% To $51m; Probiotec H1 Revenue Up 100% To $85m; Profit Up 259% To $4.4m; Medadvisor H1 Revenue Up 199% To $39m, Loss Down 29.5% To $6.7m; Cronos H1 Revenue Up 273% To $27m, Profit Up 1134% To $3.4m; Medical Dev H1 Revenue Down 24% To $10m, Loss Up 549% To $7.4m; Polynovo H1 Revenue Up 44% To $18m, Loss To $1.6m Profit; Compumedics H1 Revenue Down 7% To $17m, Profit Down 78% To $287k; Mach7 H1 Revenue Up 102% To $14m; Loss Down 94% To $419k; Mesoblast H1 Revenue Up 69% To $8m, Loss Down 3% To $68m; Cynata H1 Revenue $6.9m, Loss Down 77% To $1.1m; Impedimed H1 Revenue Up 45% To $5.2m; Loss Down 15% To $9m; Universal Bio Revenue Up 80% To $5.8m, Loss Up 38% To $10.5m; Allegra H1 Revenue Down 26% To $1.7m; Loss Up 967% To $1.3m; Regeneus Up-To $4m Loan For Japan Progenza Manufacture; Clarity Starts 2nd Neuroblastoma Trial Cohort; VGI Appoints Continuum US Distributor; L1 Capital Takes 9.9% Of Anteris; Former Immutep Chair Lucy Turnbull Returns As Director; Lou Panaccio To Replace Adherium Director Matt McNamara; Rhythm Appoints Andrea Steele Co Sec; General Counsel

Next Science Raises $10m, Plan For $5m More; Japan Approves Avita Recell System; Trajan H1 Revenue Up 17% To $44m, Profit Down 95% To $153k; Cogstate H1 Revenue Up 67% To $32m; Loss To $5.7m Profit; Austco H1 Revenue Up 15% To $16m, Profit Up 83% To $1.5m; Cyclopharm Revenue Up 21% To $18m, Loss Down 17% To $5m; Althea H1 Revenue Up 84% To $9.4m, Loss Down 14.85% To $7m; Visioneering Revenue Up 40% To $10m, Loss Down 75% To $3.2m; Telix Revenue Up 46% To $7.6m, Loss Up 79% To $80.5m; Acrux H1 Revenue Up 80% To $2m, Loss Down 30% To $5.5m; Genetic Technologies H1 Revenue Up To $2m; Loss Up 12% To $3.9m; Micro-X H1 Revenue Down 40% To $1.45m, Loss Up 87% To $9m; Uscom H1 Revenue Down 52% To $1.1m, Loss Up 250% To $943k; Ena, COPD Foundation Partner For Pan-Antiviral Nasal Spray; MTP Connect Adelaide Biomed City ‘Innovation Intermediary’; Zelira To Buy Health House For Scrip; $1.5m Loan; Argenica Completes ARG-007 Genotoxicity Studies; Hydrix Requests ‘Capital Raising’ Trading Halt; Creso Takes ‘Capital Raising’ Trading Halt To Suspension; Antisense, Chicago’s Northwestern Work On ‘Long Covid’; Starpharma Appoints Ex-CSL Executive Dr Jeff Davies Director

Chimeric Institutional Rights Raise $7.4m; Retail $10.7m To Go; Anteris L1 Capital Options Raise $5m; Clinuvel H1 Revenue Up 57% To $25m; Profit Down 10% To $6m; Alcidion H1 Revenue Up 16% To $13m, Loss Up 360% To $6.3m; IDT H1 Revenue Up 74% To $8.6m, Profit Up 8% To $1.2m; Next Science Revenue Up 160% To $12m; Loss Down 22% To $13m; Cryosite H1 Revenue Up 18% To $5.8m, Profit Up 175% To $782k; Rhinomed H1 Revenue Up 93% To $3.7m, Loss Down 41% To $3.2m; Control Bionics H1 Revenue Up 18% To $2m; Loss Up 193% To $3m; Invion H1 Revenue Up 4.4% To $1.3m, Loss Up 23% To $1.05m; Next Science Requests ‘Capital Raising’ Trading Halt; Brazil Patent For Inoviq Bard1 Cancer Diagnostic; Race: Zantrene Combination ‘Synergy’ For Leukaemia, In-Vitro; Pharmaust: ‘Monepantel Effective For Leukaemia, In-Vitro’

Cochlear H1 Revenue Up 10% To $821m, Profit Down 28% To $169m; Nanosonics H1 Revenue Up 40% To $61m, Profit Up 165% To $3.9m; Somnomed H1 Revenue Up 10% To $34m, Loss Down 14% To $2.95m; Atomo H1 Revenue Up 17% To $5.3m, Loss Down 5% To $2.4m; Dorsavi H1 Revenue Down 14% To $1.6m, Loss Up 177% To $907k; Bioxyne H1 Revenue Up 12.2% To $1.4m, Loss To $5k Profit; Editorial: Your R&D Tax Incentive Is Not Revenue; Microba Raising $30m For Gut Health Tests, Treatments; Chimeric Rights Offer To Raise $18m; Creso Requests Capital Raising Trading Halt; Proteomics Promarkerd Prepares For Australian Rebate; Emyria Expands MDMA Analogues

Subscribe to Biotech Daily